Japanese Patent Intelligence

Neuro-Imaging Breakthrough: 13 Years Exclusive, 20% Faster Drug Development

~$1.5M/year estimated R&D cost reduction per facility (est.).

Precision Hydrogel: ~20% Higher Cell Purity, ~30% Faster Cultured Meat Production

~$100K/year estimated R&D cost reduction per facility (est.)

High-Accuracy, Non-Invasive AFib Detection Cuts Medical Costs by ~30%

~$1M/year estimated healthcare cost reduction per facility (est.)

20x Brain Drug Delivery Efficiency Boost for Neurological Therapies

~$6.5B/year estimated new market opportunity (est.)

Accelerate Drug Discovery by 30% with Rapid Neural Dynamics Detection

~$1.5M/year estimated drug discovery development cost reduction per project (est.)

Alzheimer's Breakthrough: Novel Peptide Accelerates Time-to-Market by 3.5 Years

~$80M–$500M/year estimated new revenue creation per market segment (est.)

Automate Flexible Item Handling: 1.5× Stability, 66% Cost Savings

~$350K/year estimated automation cost savings per facility (est.)

Precise Gene Control by Light: Accelerate R&D by 30%

~$80K/year estimated R&D cost reduction per facility (est.)

Rapid Microbial Detection: ~4x Faster, Cuts Labor Costs by ~$65K/year

~$200K/year estimated inspection cost reduction and loss mitigation per facility (est.)

Sprayable Adhesion Barrier: Cut Re-operations by ~20%, Reduce Costs by ~65%

~$350K–$650K/year estimated medical cost reduction per facility (est.)

Boost Cerebral Artery Dissection Diagnosis by 30% with AI Imaging

~$350K/year estimated medical cost reduction per facility (est.)

Targeting Cell Nuclei: High-Selectivity Peptide, <40 Amino Acids

~$1M/year estimated drug development cost reduction per facility (est.)

Boost Cell Culture Efficiency by 30%, Halve Handling Time

~$200K/year estimated cost savings per facility (est.)

Prion Disease: Novel Drug Accelerates Development by 3 Years, Unlocking Billions

~$10B/year estimated R&D cost and opportunity loss avoidance, plus billions in revenue opportunity (…

2x Lentiviral Vector Yield, Accelerating Gene Therapy Scale-Up

~$1.0M/year estimated manufacturing cost reduction per facility (est.)

Novel Compound Boosts Cancer Treatment Efficacy by 1.5×

~$6.5M/year estimated new revenue per specific cancer market (est.)

Growth Factor-Free Angiogenesis: Cuts PAD Treatment Costs by ~50%

~$20M/year estimated healthcare cost reduction per country (est.)

1.5× Productivity, ~20% Cost Reduction in Microalgae Cultivation

~$200K/year estimated cost savings and revenue increase per facility (est.)

Targeted Gastric ILC2 Activation Cuts Infection Risk by ~33%

~$330M/year estimated healthcare cost reduction (est.)

PPARδ Activation: 1.5× Exercise Endurance, ~30% Metabolic Improvement

~$20M/year estimated new market creation potential (est.)

Safe Heart Rate Reduction: Boost Exercise Endurance by ~20%

~$10M/year estimated market creation potential (est.)

Live-Cell mRNA Visualization: Accelerate R&D by ~20%, cut costs by ~$1M/year

~$1M/year estimated R&D cost reduction per facility (est.)

Accelerates Drug Development by up to 2 Years with Comprehensive Pharmacogenomics

~$1.5M/year estimated drug development cost reduction per facility (est.)

Novel V-ATPase Inhibitor: Cuts Drug Discovery Time by 20%, ~$1M Annual Savings

~$1.0M/year estimated healthcare cost reduction and 20% development time reduction (est.)